14/11/2025
November is .
is often diagnosed late, when treatment options are limited.
Our SAFE-D trial is evaluating a blood test, developed by ClearNote Health, which aims spot the very earliest signs of the developing. The trial uses blood samples from people with a recent diagnosis of type 2 diabetes – a known risk factor and potential sign or symptom of pancreatic cancer.
Find out more about the study - https://safe-d.uk/
University Hospital Southampton NHS Foundation Trust, Health Research Southampton, University of Southampton, University of Southampton Medicine, Cancer Research UK, Pancreatic Cancer UK, Pancreatic Cancer Action